EyePoint Pharmaceuticals

Press Releases

pSivida Announces Poster and Oral Presentation on Controlled Release of Avastin® from Tethadur™ Biodegradable Matrix at the 2016 Controlled Release Society Annual Meeting
Jul 08, 2016
WATERTOWN, Mass. , July 08, 2016 (GLOBE NEWSWIRE) -- pSivida Corp (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that pSivida's Dr. Catherine Kelly will present a poster and oral presentation on "The Controlled
pSivida Announces Successful Completion of Two Preclinical Studies of Durasert™ Sustained-Release Insert Delivering Repurposed Cancer Drug to Treat Wet AMD
Jul 05, 2016
Promising Results for Potential Sustained Treatment of Wet AMD Using a TKI
pSivida Corp. Provides Company Update and Reports Third Quarter FY 2016 Results
May 05, 2016
WATERTOWN, Mass. , May 05, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its third fiscal quarter ended March 31,
pSivida CEO to Present at 2016 International Symposium of Ocular Pharmacology and Therapeutics
May 04, 2016
WATERTOWN, Mass. , May 04, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton , president and CEO, will present "Changing the Treatment Paradigm
pSivida's Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe
May 02, 2016
WATERTOWN, Mass. , May 02, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA),  a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the European Commission granted orphan medicinal product designation to Medidur™ for
pSivida Corp. Announces Third Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information
Apr 27, 2016
WATERTOWN, Mass. , April 27, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the third quarter of fiscal year 2016 will be released after
pSivida to Present at the Sidoti Spring 2016 Emerging Growth Convention
Mar 24, 2016
WATERTOWN, Mass. , March 24, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the company will be presenting at the Sidoti Spring 2016 Emerging Growth Convention at
Additional Favorable Six-Month Safety Results for pSivida's Medidur™ for Posterior Uveitis
Mar 15, 2016
Small Average Increase in IOP Relative to Control Comparable Percentage Treated with Eye Drops for Elevated IOP WATERTOWN, Mass. , March 15, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye
pSivida Corp. Provides Company Update and Reports Second Quarter FY 2016 Results
Feb 08, 2016
WATERTOWN, Mass. , Feb. 08, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV), (ASX:PVA),  a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its second fiscal quarter ended
pSivida Corp Announces Second Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information
Feb 01, 2016
WATERTOWN, Mass. , Feb. 01, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the second quarter of fiscal year 2016 will be released after
pSivida CEO to Present at 18th Annual Bio CEO & Investor Conference February 9
Jan 28, 2016
WATERTOWN, Mass. , Jan. 28, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drugs for treating eye diseases, today announced that Dr. Paul Ashton , President and CEO, will present at the 18 th Annual Bio CEO & Investor Conference,
pSivida Closes $17.8 Million Offering
Jan 13, 2016
WATERTOWN, Mass. , Jan. 13, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the closing yesterday of the underwritten public offering of 4,440,000 shares of its common
pSivida Announces Pricing of $16 Million Public Offering of Common Stock
Jan 07, 2016
WATERTOWN, Mass. , Jan. 07, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at a
pSivida Announces Proposed Public Offering of Common Stock
Jan 06, 2016
WATERTOWN, Mass. , Jan. 06, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that it intends to offer and sell shares of its common stock in a proposed underwritten
pSivida Plans Medidur™ EU Marketing Approval Application Based on Single Phase 3 Clinical Trial
Dec 28, 2015
WATERTOWN, Mass. , Dec. 28, 2015 (GLOBE NEWSWIRE) -- pSivida Corp.  (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that it plans to file for EU marketing approval of Medidur™ for chronic non-infectious
pSivida's Medidur™ Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurrence of Posterior Uveitis (p Less Than 0.00000001)
Dec 22, 2015
Statistical Significance in Improvement in Visual Acuity and Reduction in Systemic Therapy  Medidur™, pictured below the pencil, is an injectable micro-insert designed to treat posterior uveitis. Injected into the back of the eye, it provides sustained release of 0.18 mg of a corticosteroid
pSivida Corp. Provides Company Update and Reports First Quarter FY 2016 Results
Nov 05, 2015
WATERTOWN, Mass. , Nov. 05, 2015 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV), (ASX:PVA),  a leader in the development of sustained release, drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its first fiscal quarter ended
pSivida Corp Announces First Quarter FY 2016 Financial Results Release Date and Conference Call Information
Oct 30, 2015
WATERTOWN, Mass. , Oct. 30, 2015 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the first quarter of fiscal year 2016 will be released after
pSivida Announces NDA for Medidur™ Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs
Sep 28, 2015
Top-Line Data from First Trial Expected December 2015 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, announced that the Company now plans to file a New Drug Application
pSivida CEO to Present at Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015
Sep 14, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton , President and CEO, will present at the Ladenburg Thalmann 2015 Healthcare Conference
Displaying 81 - 100 of 327
EyePoint Pharmaceuticals